Background: Hospital antibiograms, which are commonly used to determine empiric antibiotic therapy and as a tool in stewardship in a given institution, are open to bias when combining susceptibility results from various sources, hospital locations, and patient groups. Methods: We assessed such differences, using Pseudomonas aeruginosa as a test case, with susceptibility data from 2008 through 2010 in our institution. Each year's data were analyzed separately. A variety of specific or subcategorical antibiograms were compared with each other as well as with versions including all tested isolates and those with results from inpatients and outpatients only. Statistical significance was determined at the .01 level using either chi-square or Fisher exact test, and clinical significance was defined as $10 percentage points. Results: A variety of clinically significant differences were found that illustrated important differences within the intensive care unit environment and based on population, specifically adult versus pediatric. Concordance between statistically significant and clinically significant differences was poor. Conclusion These results corroborate and extend previous similar observations and point to the potential importance of subanalyses in preparing the annual hospital antibiogram.
T he use of antibiograms to help select empirical antibiotic therapy for suspected infection with likely or known pathogens is a well-established practice. 1, 2 However, it has been the subject of some debate whether assembled antibiograms based upon published standards are optimal in this regard. According to current standards, antibiograms are prepared by including all tested isolates (excluding duplicates from the same patient and surveillance cultures) for a specific time period. 1 However, this approach would include testing results from diverse populations and locations within the institution, and important differences for distinct patient groups or location could be masked within the overall summary numbers. Hospital antibiograms could be limited to inpatient isolates only, but even then they may include susceptibility results from both adult-and pediatric-derived isolates. The Clinical and Laboratory Standards Institute (CLSI) guideline in this regard suggests that institutions may wish to consider and/or prepare subanalyses or custom antibiograms to address this issue. It has been shown that unit-specific antibiograms can vary substantially from hospitalwide (inclusive of all inpatient and/or outpatient isolates) summaries. Further, we have illustrated that inclusion of isolates from specific populations (ie, Pseudomonas aeruginosa isolates from cystic fibrosis patients) can skew the hospitalwide susceptibility numbers in a misleading way. 3 As one considers the diversity of isolates, it becomes clear that they vary by patient group, hospital location, and source. All of these observations beg the question as to whether hospitalwide antibiograms suffer in their intent to inform the clinician due to the heterogeneity of sources. Further, if they have this limitation, what is the potential extent that any subanalysis might vary from the hospital's overall or hospitalwide antibiogram?
A number of studies have noted that inappropriate empiric therapy has been linked to increased morbidity and mortality, [4] [5] [6] including some therapy specifically focusing on infections with P. aeruginosa, [7] [8] [9] and it is therefore important that the most relevant susceptibility data be supplied to clinicians to guide their empirical treatment decisions. It was the purpose of the present study to investigate the degree of variance from a hospitalwide antibiogram to more targeted antibiograms for specific units, patient populations, or specific sources.
MATERIALS AND METHODS
The Medical University of South Carolina Medical Center is a 709-bed health care facility that is designated as a level 1 trauma center. It comprises 5 inpatient facilities including 2 adult hospital buildings and a children's hospital that includes an additional 50 neonatal special care beds. Some of these facilities are physically connected as contiguous space. Annual admissions exceed 34,000, and annual outpatient visits exceed 950,000. The study was approved by the Medical University's institutional review board.
The current analysis utilized susceptibility results for all tested P. aeruginosa isolates evaluated by our Clinical Microbiology Laboratory for the years 2008 through 2010. This organism was selected for study in this exercise as it is a common nosocomial pathogen. Susceptibility was determined by disk diffusion in compliance CLSI standards for those years. 10, 11 Tested antibiotics of interest included piperacillin/tazobactam, cefepime, ceftazidime, imipenem, meropenem, ciprofloxacin, levofloxacin, amikacin, gentamicin, and tobramycin. Susceptibility data were available for each of these drugs for all 3 years, except for ceftazidime and imipenem which were not available for 2010. A variety of annual antibiograms were assembled and, in all cases, no duplicates or surveillance isolates were included. An antibiogram that included all tested isolates from both inpatient and outpatients was constructed as were versions that included inpatient or outpatient isolates only. The latter included both adult and pediatric isolates from all sources, which is consistent with current practice within many institutions for the production of annual antiobiograms. Where the number of isolates in a category or subcategory permitted (ie, $15 per year), more exclusive antibiograms (subcategories) were prepared including adult inpatient, pediatric inpatient, all adult intensive care units (combined), all pediatric intensive care units (combined), the adult medical intensive care unit (MICU), and the surgical trauma intensive care unit (STICU). Lastly, a number of additional subcategorical antibiograms were constructed based on isolate source. These were created separately for adult and pediatric classes and included blood, lower respiratory, urine, and ''other''; these were further divided into inpatient and outpatient isolates. Results for these various versions were compared, but the main analysis contrasted the various subcategories with the inpatient antibiogram. In total, 496 comparisons were made. In 5 of these, the number of organisms in a given subcategory was less than 30; although none was associated with statistical or clinically significant differences, they were not considered further.
Comparisons of rates of susceptibility to the tested antibiotics were compared among the various antibiograms using chi-square or Fisher exact test, as appropriate. Significance was determined at P 5 .01 as a conservative estimate of significance due to the multiple comparisons being made. Each annual antibiogram was assessed separately in relation to that year's subcategory antibiograms. Antibiograms from 3 separate years were examined (within that year) to determine whether the types of differences found were consistent from year to year. In addition to the statistical analysis, a determination of clinical significance was also made, with a difference in susceptibility rate of $10% being considered important/significant. This level was chosen as it was believed that it would be sufficient to alter a clinician's choice of empiric coverage when considering an institution's antibiogram.
RESULTS
The results of the statistical comparison of subcategories to the all inpatient antibiograms for each year of interest are presented in Table 1 . Only results for those antibiotics for which all 3 years of data were available are included. Although few statistically significant differences were found, many clinically significant observations were apparent ( Table 2) . The most frequently detected differences were found in comparing the MICU results to those of the total inpatient (adult and pediatric isolates/all sources) antibiogram or the adult inpatient (adult only/all sources) antibiogram. There were also several instances in which results from this ICU varied from those for all adult ICUs combined. A sufficient number of isolates for analysis was only available in 2010 for the STICU. Results from comparisons of that unit to other subcategories yielded a variety of clinically significant differences, including with the MICU and the inpatient antibiograms. Susceptibility rates from the adult inpatient antibiogram often differed, in a clinically significant manner, from the pediatric inpatient version.
The antibiotics associated with the greatest number of clinically significant differences were the fluoroquinolones, whereas those with the least number were the cephalosporins. Statistically or clinically significant differences were not consistent from one antibiotic to the next nor were they consistent from year to year. Further, there was poor concordance between statistical and clinical significance ( Table 2) .
DISCUSSION
The CLSI provides guidance for the construction (what data to include) and dissemination (to whom and how often) of antibiograms. Regardless, antibiograms present data that may be useful in making for-mulary decisions and setting antimicrobial use policies or in the analysis of antimicrobial use-resistance relationships. Information provided by antibiograms can be key to many antimicrobial stewardship initiatives and have been listed as a minimum requirement for such programs in a recently published policy statement. 12 However, the main use is undoubtedly as a guide to empiric antibiotic selection. As the selection of appropriate initial therapy is of paramount importance in a variety of serious infections, it is vital that that information presented in the antibiogram be reliable for Only those comparisons with one or more clinically significant differences for a given year are displayed; no result/data indicates a difference ,10%.
that purpose. In following CLSI guidance, an institution could prepare an antibiogram reflecting all tested isolates for the period of interest (excepting duplicates and surveillance specimens). However, by combining susceptibility results from all locations, patient populations, and sources, important distinctions or differences that exist for subcategories may be masked. Such differences have been well described, and a number of reports have been published that point out potential pitfalls of combining all tested isolates into one hospitalwide antibiogram. [13] [14] [15] Several studies have illustrated differences between antibiograms reflecting isolates from patients in ICUs to hospitalwide versions. [16] [17] [18] [19] Our results are consistent with this observation. This is actually quite predictable as numerous studies have documented higher levels of antibiotic use with resultant higher rates of resistance in the ICU environment. [20] [21] [22] [23] [24] [25] In a report from Project ICARE, Fridkin and colleagues illustrated higher resistance rates in ICU compared to non-ICU settings, which, in turn, exhibited higher rates than in isolates from outpatients. 26 Moreover, important differences may exist in different ICUs in the same hospital as noted here and by others. 18 We have previously reported the consequences of including cystic fibrosisderived isolates of P. aeruginosa with all others on the hospitalwide rates of susceptibility. 3 This practice produces a lower susceptibility rate than one would find if such isolates were excluded or analyzed separately. Another valid question would be whether an antibiogram constructed solely with documented infection-associated isolates would vary from the typical hospitalwide antibiogram, which is typically based upon all tested isolates. It stands to reason that such antibiograms could be quite different. However, a study of this issue with infection-based data from ICU patients found no important differences from the hospitalwide antibiogram except in the case of methicillinresistant Staphylococci. 27 At the same time, a different report comparing the hospitalwide antibiogram to one including only isolates associated with hospital-acquired infections described a variety of important differences in resistance rates with a number of organisms. 28 We have taken these observations another step, albeit with only one organism, and have shown that not only do differences exist when comparing inpatient versus outpatient and ICU versus hospitalwide, but that distinctions in pediatric versus adult (or hospitalwide) and specific source versus hospitalwide may also be considerable and clinically relevant. Our results corroborate those of previous investigations described previously. A number of specific findings merit further discussion. Pediatric and adult inpatient results were often clinically significantly different such that combining results from these 2 population groups would be unwise. Clinically significant differences were seen with all drugs over all years, but the comparisons that differed varied from drug to drug and year to year. For example, the MICU versus all inpatient antibiogram differences seen in 2008 and 2009 were not seen in 2010. This would indicate that such comparative analyses need to performed on a yearly basis.
Several issues should be appreciated in weighing our results and their potential implications. This was a single-center analysis, and our results may not be consistent or relevant to those of other institutions. Also, we limited our assessment to one pathogen, P. aeruginosa, and a select group of antibiotics, so our findings might not apply to other organisms and/or drugs. As an example, no clinically significant differences were seen in comparing urine isolates to those of other antibiogram categories. This would be a less likely finding if a more common urinary pathogen were assessed. We chose to study P. aeruginosa because it is a common cause of nosocomial infections and is well known to have multiple resistance mechanisms affecting susceptibility to several classes of antibiotics. For these reasons, it appeared to be an appropriate representative pathogen with which to test our hypothesis. However, it may represent a worst case scenario, and other common pathogens should be considered and analyzed as well. Our definition of clinical significance could certainly be questioned. Choosing one value is, at best, an oversimplification; the magnitude of difference that would influence empiric antibiotic choices varies from clinician to clinician and would likely be influenced by type of infection and other factors. Other issues should also be kept in mind in interpreting our findings. One could certainly pose the question of whether our results would apply similarly to hospital-and communityacquired infections/pathogens. As dates of admission and organism isolation were not considered, we are unable to answer this logical question. Other investigators have illustrated that pathogens involved in hospital-acquired infections may have higher resistance rates. 27, 28 Lastly, a small number (5) of comparisons involved subcategories with between 15 and 29 isolates, whereas the current CLSI guidance requires a minimum of 30. As already noted, none of these 5 instances were associated with statistically or clinical significant differences and therefore had no bearing on our conclusions.
Our results would suggest that more specific antibiograms, based upon location, patient type, or source, may provide better guidance for empiric therapy decisions based on those subgroups, assuming considerable diversity in these variables and adequate numbers of tested organisms. Institutions would be well advised to perform and assess subanalyses, as suggested in CLSI guidance, to determine what antibiogram information or format best informs its clinicians in making empiric antibiotic prescribing decisions.
